Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala PharmaceuticalsBusiness Wire • 02/06/24
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceBusiness Wire • 02/05/24
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology PlatformBusiness Wire • 01/08/24
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer TherapiesBusiness Wire • 10/03/23
Shareholder Alert: Ademi LLP investigates whether Immunome, Inc. has obtained a Fair Price in its Private Placement and its transaction with MorphimmunePRNewsWire • 06/30/23
IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to ShareholdersBusiness Wire • 06/29/23
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer TherapiesBusiness Wire • 06/29/23
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor ActivityBusiness Wire • 05/23/23
Immunome, Inc. (IMNM) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 04/20/23
Recent Price Trend in Immunome, Inc. (IMNM) is Your Friend, Here's WhyZacks Investment Research • 03/22/23